[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]
- PMID: 16252510
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]
Abstract
The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus and increase of fat accumulation in adipocytes. The blockade of the cannabinoid system (CB1) by the specific inhibitor (rimonabant) decreases food intake and adiposity in animals and in humans. Moreover rimonabant lowers tobacco addiction. Clinical studies (RIO-LIPIDS and RIO-EUROPE) have recently confirmed that rimonabant combined with a hypocaloric diet over 1 year, promoted significant decrease of body weight, waist circumference and improvement of dyslipidemia. Rimonabant was well tolerated with mild and transient side effects. The future place of rimonabant in the strategy of obesity is still to be clarified.
Similar articles
-
[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].Rev Med Brux. 2005 May-Jun;26(3):165-8. Rev Med Brux. 2005. PMID: 16038141 French.
-
Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.Pharmacol Rep. 2009 Mar-Apr;61(2):217-24. doi: 10.1016/s1734-1140(09)70025-8. Pharmacol Rep. 2009. PMID: 19443932 Review.
-
The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.J Clin Pharm Ther. 2007 Jun;32(3):209-31. doi: 10.1111/j.1365-2710.2007.00817.x. J Clin Pharm Ther. 2007. PMID: 17489873 Review.
-
Endocannabinoid control of food intake and energy balance.Nat Neurosci. 2005 May;8(5):585-9. doi: 10.1038/nn1457. Nat Neurosci. 2005. PMID: 15856067 Review.
-
[Endocannabinoid and endocannabinoid receptor antagonists].Med Monatsschr Pharm. 2005 Feb;28(2):40-3. Med Monatsschr Pharm. 2005. PMID: 15727333 Review. German. No abstract available.
Cited by
-
Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.Curr Diab Rep. 2017 Sep 14;17(10):99. doi: 10.1007/s11892-017-0924-x. Curr Diab Rep. 2017. PMID: 28913816 Review.
-
Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.Shock. 2009 Dec;32(6):614-20. doi: 10.1097/SHK.0b013e3181a4fd8f. Shock. 2009. PMID: 19295473 Free PMC article.
-
Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.Acta Pharmacol Sin. 2025 Jun;46(6):1495-1510. doi: 10.1038/s41401-024-01472-9. Epub 2025 Feb 5. Acta Pharmacol Sin. 2025. PMID: 39910211 Review.